Parenteral Manual

Mycophenolate mofetil (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
CellCept®, MMF
Immunosuppressant agent -NON-CYTOTOXIC HAZARDOUS
Original Date: 
August 2005
Revised Date: 
June 2015
  • For the prophylaxis of organ rejection in patients receiving renal transplants and in patients  receiving allogenic cardiac or hepatic transplants
Reconstitution and Stability: 
  • Available as 500 mg lyophilized powder vial
  • Vials are stored at room temperature
  • Reconstitute each vial using 14 mL of D5W to make a 33.3 mg/mL solution; gently shake to mix
  • Reconstituted solution will be slightly yellow
  • Further dilute with D5W to a concentration of 6 mg/mL
  • Stable 7 days at room temperature when diluted to 1 - 10 mg/mL
  • Store diluted infusion solution and reconstituted vials at room temperature
  • Prepare drug in biohazard hood.  Handle and dispose of biohazard waste as per hospital policy
  • Solutions Compatible: D5W only

INCOMPATIBLE with all other IV solutions

DO NOT administer other IV drugs concurrently via the same infusion line



(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct


IV Intermittent Infusion

Usual dilution: 6 mg/mL
Infusion time: > 2 hours; peripheral or central line

IV Continuous Infusion NO




(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 10-40 mg/kg/day IV divided Q12H

- Renal Transplant:

  • 600-1200 mg/m2/day PO divided Q12H; MAX of 3 g/day
  • Convert PO to IV at a ratio of 1:1
  • Patients should be switched to the oral route as soon as they can tolerate oral medication
  • IV can be administered for up to 14 days
Potential hazards of parenteral administration: 
  • Phlebitis and thrombosis via peripheral route
  • Diarrhea, vomiting
  • Leukopenia, sepsis
  • Numerous adverse effects have been reported in clinical trials; those effects reported in >20% of patients include: body aches, abdominal pain, fever, anemia, urinary tract infections, hypertension, peripheral edema, constipation, nausea.  Refer to product monograph in CPS for complete listing.
  • Anaphylaxis has been reported (rarely)-contraindicated in patients allergic to polysorbate 80 (TWEEN) or mycophenolate mofetil/mycophenolic acid
  • GI bleed and severe neutropenia have been reported (rarely)
  • Monitoring parameters: CBC with differential, platelets, serum electrolytes, glucose, phosphate, cholesterol, renal function tests, blood pressure
  • Because of risk of teratogenicity, caution should be exercised in handling and preparation.  Avoid skin contact of the solution.  If contact occurs, wash thoroughly with soap and water.  Rinse eyes with plain water.
  • Should be administered within 24 hours following transplantation
  • May be used concomitantly with cyclosporine and corticosteroids

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.